ArticleMolecular therapy. Nucleic acids2025
Antisense oligonucleotide-based switches for conditional translation of synthetic mRNA.
Article in Molecular therapy. Nucleic acids, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Synthetic messenger RNA (mRNA) therapeutics requires precise control over their translation to minimize off-target effects. We introduce an antisense oligonucleotide (ASO)-based switch concept that regulates synthetic mRNA translation based on the presence of a complementary trigger RNA (trigRNA). We evaluate variations in ASO hybridization length, position, and chemistry in rabbit reticulocyte lysate (RRL) assays and HEK293T cells. In addition, we explore multiple ASO delivery strategies, including lipid and dendrimer conjugation. Our experiments demonstrate that increased ASO hybridization length and concentration enhance suppression while also improving the OFF/ON dynamic range in the presence of trigRNA. Cell experiments revealed that cholesterol or dendrimer-conjugated phosphorodiamidate morpholino oligonucleotides (PMOs) improved uptake leading to increased translational suppression which facilitated moderate trigRNA-dependent activation. Alternatively, PMOs that exhibit higher complementarity for the trigRNA than for the mRNA reached a dynamic range of 86.4 in RRL and 1.79 in HEK cells. We conclude that the presented ASO-based switch concept provides a novel mRNA translation control strategy, which does not rely on expressing exogenous proteins. While RRL assays demonstrate robust switching, intracellular efficacy is currently constrained by ASO delivery and intracellular dilution. Future optimization of ASO stability and maintaining intracellular suppression will be critical for therapeutic applications.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.